GlassScriptPhysician profile
Brandon D Jensen
NPI 1821476797
$10,420.45
in general payments reported to CMS, 2019-2025
45 companies · $3,558 in 2025
The $3,558 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $243 · 2022: $870 · 2023: $2,767 · 2024: $2,983 · 2025: $3,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,248 · Education: $59.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,247.98 |
| Education | $59.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,375.34 | 2022-2025 | Dupixent |
| Pfizer INC. | $878.08 | 2022-2025 | |
| Novo Nordisk INC | $769.83 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $606.97 | 2022-2025 | Otezla, Repatha, Tezspire |
| Abbvie INC. | $484.98 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $473.83 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $472.22 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Glaxosmithkline, LLC. | $467.27 | 2023-2025 | Nucala, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $466.91 | 2022-2025 | Fasenra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $447.58 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $447.37 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $342.36 | 2022-2025 | Jardiance |
| Antares Pharma, INC. | $316.75 | 2022-2025 | Xyosted |
| Lilly USA, LLC | $265.10 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Axsome Therapeutics, INC. | $240.02 | 2022-2025 | Auvelity, Symbravo |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $239.78 | 2023-2025 | Trintellix, Cuvitru |
| Esperion Therapeutics, INC. | $237.68 | 2021-2025 | Nexletol |
| Radius Health, INC. | $146.60 | 2023-2025 | Tymlos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $126.61 | 2023-2025 | Xifaxan, Trulance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $126.19 | 2025 | Lifevest |
| Mylan Specialty L.P. | $123.82 | 2023-2024 | Yupelri |
| Genzyme Corporation | $117.80 | 2023-2025 | |
| Abbott Laboratories | $112.73 | 2024-2025 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $112.13 | 2022-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $104.73 | 2022-2025 | Capvaxive, Gardasil 9, Gardasil |
| Astellas Pharma US INC | $95.69 | 2023-2024 | Veozah, Myrbetriq |
| Phathom Pharmaceuticals, INC. | $88.98 | 2024-2025 | Voquezna |
| Lundbeck LLC | $68.07 | 2024-2025 | Rexulti |
| Horizon Therapeutics Plc | $67.79 | 2023 | Krystexxa |
| Sanofi-Aventis U.S. LLC | $59.80 | 2025 | |
| Halozyme INC | $59.38 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $58.18 | 2022-2025 | Zoryve, Livalo, Seglentis |
| Janssen Biotech, INC. | $56.72 | 2024-2025 | Simponi Aria, Stelara, Simponi |
| Almatica Pharma LLC | $48.59 | 2025 | Teriparatide, Loreev Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $43.51 | 2022 | |
| Sumitomo Pharma America, INC. | $42.72 | 2023-2024 | Gemtesa |
| Intra-Sana Laboratories | $39.39 | 2023 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Viatris Specialty LLC | $38.29 | 2025 | Yupelri |
| Exact Sciences Corporation | $35.38 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Insmed, INC. | $25.53 | 2024 | Arikayce |
| Kyowa Kirin, INC. | $20.38 | 2023 | Crysvita |
| Seqirus USA INC | $20.12 | 2025 | Fluad, Flucelvax |
| Paratek Pharmaceuticals, INC. | $19.26 | 2025 | Nuzyra |
| Tolmar, INC. | $15.35 | 2024 | |
| Ironwood Pharmaceuticals, INC | $14.64 | 2023 | Linzess |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Jensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.